启明创投

Future Intelligent Raises Tens of Millions of RMB in Pre-A+ Round, Co-Led by Qiming Venture Partners

Future Intelligent focuses on R&D and scenario innovation for AI-powered office hardware.

Qiming Venture Partners Weekly | Portfolio News and Updates Vol. 14, 2025

Celebrating milestone moments with Qiming Venture Partners' portfolio companies

Qiming Venture Partners Portfolio Companies Featured in QbitAI 2025 AIGC Companies and Products List

The ranking aims to offer an objective lens for understanding application trends in China's generative AI space, spotlighting early adopters and benchmark cases that dare to experiment and innovate.

Qiming Venture Partners and Portfolio Companies Win Multiple ChinaVenture Awards, Including Top 5 China VC Firm of 2024

The "ChinaVenture Rankings" have been published for 19 consecutive years, recognized within the industry for their professionalism, authority, and rigor. They are widely regarded as a bellwether for China's equity investment sector and serve as a key reference for capital commitments from many large institutional LPs.

Qiming Star | Ark Biosciences Announces Latest Research Results for First RSV-Specific Antiviral Drug Ziresovir Published in The Lancet Child & Adolescent Health | Bilingual

This study, the world's first Phase 3 clinical trial covering RSV-infected infants under six months of age, successfully fills the evidence gap for targeted treatment approaches in this high-risk population and provides critical evidence for building a comprehensive RSV disease management system.

Qiming Venture Partners Portfolio Companies Dominate China AI Top 300 List

The rankings prioritize technical capability and commercialization potential, offering a panoramic survey of China's systematic breakthroughs in AI technology.

Qiming Venture Partners Issues Stern Statement on Fraudulent Investment Scheme

Qiming Weekly | Qiming Venture Partners Portfolio Funding and Updates Roundup Vol. 13, 2025

Following Qiming Venture Partners' portfolio companies' milestone moments with you

Qiming Venture Partners-Backed Belief BioMed Announces Approval of China's First Hemophilia B Gene Therapy Drug Xinjining®

As China's first independently developed gene therapy for hemophilia B, Xinjiuning® will offer patients a completely new treatment option, with the potential to free them from a lifetime of frequent intravenous injections and help them return to a life without constraints.

Qiming Venture Partners portfolio company WeRide adopts BlackBerry QNX to build ultra-safe ADAS solution

By leveraging QNX's foundational software, WeRide has not only enhanced the performance of its driver-assistance systems, but also advanced autonomous vehicles as a core component of smart cities — easing traffic congestion, reducing carbon emissions, and improving road safety.